

MAGLUMI AFP (Prenatal Screening) (CLIA)



130214001M



100



**Shenzhen New Industries
Biomedical Engineering Co., Ltd**
4/F,Wearnes Tech Bldg,
Science & Industry Park,
Nanshan,Shenzhen,518057CHINA
Tel. + 86-755-86028224
Fax.+ 86-755-26654850



Lotus Global Co., Ltd
15 Alexandra Road
London
UK
NW8 0DP
Tel. + 44-20-75868010
Fax.+ 44-20-79006187

FOR PROFESSIONAL USE ONLY

Store at 2-8 °C



COMPLETELY READ THE INSTRUCTIONS BEFORE
PROCEEDING



SYMBOLS EXPLANATIONS



Authorized Representative in the European community




Manufacturer



Consult instructions for use



Contents of kit



In vitro diagnostic medical device



Batch code



Catalogue number



Use by



Temperature limitation
(store at 2-8 °C)



Sufficient for



Keep away from sunlight



Keep upright for storage

INTENDED USE

The kit has been designed for the quantitative determination of AFP (Prenatal Screening) in human serum.

The method can be used for samples over the range of 1.13-450 IU/ml.

The test has to be performed on the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600, Maglumi 1000, Maglumi 1000 Plus, Maglumi 2000, Maglumi 2000 Plus, Maglumi 3000 and Maglumi 4000).

SUMMARY AND EXPLANATION OF THE TEST

Alpha-fetoprotein (AFP) is a glycoprotein with a high molecular weight (approx. 68,000 D) consisting of a single polypeptide chain. AFP, which belongs to the group of oncofetal proteins, is produced by the yolk sac and in the fetal liver.

In oncology, AFP is determined in patients with liver-cell carcinoma or germ-cell tumors (non-seminomatous tumors of the testes; endodermal sinus tumor of the ovaries). AFP plays an important role for pregnancy monitoring, too. During pregnancy, AFP levels in maternal blood continuously increase. Between weeks 28 to 32, a maximum is reached; after this period, a decrease can be observed until delivery. In the amniotic fluid, the maximum is already achieved between the 13th and 15th week of gestation. Elevated AFP levels in early pregnancy indicate neural tube defects (spina bifida, anencephaly). Lower AFP concentrations in maternal serum are indicative of Down's syndrome.

The determination of serum AFP during therapeutic monitoring provides valuable information about the success or failure of treatment as well as about the occurrence of recidivation.

PRINCIPLE OF THE TEST

Sandwich immunoluminometric assay:

Use an anti-AFP monoclonal antibody to label ABEI, and use another monoclonal antibody to label FITC. Sample, Calibrator or Control, with FITC Label, ABEI Label and magnetic microbeads coated with anti-FITC are mixed thoroughly and incubated at 37°C, forming a sandwich; After sediment in a magnetic field, decant the supernatant, then cycle washing for 1 time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of AFP present in samples.



KIT COMPONENTS

Material Supplies

| Reagent Integral for 100 determinations | |
|--|-------|
| Nano magnetic microbeads: TRIS buffer, 1.2%(W/V), 0.2%NaN ₃ , coated with sheep anti-FITC polyclonal antibody. | 2.5ml |
| Calibrator low: bovine serum, 0.2%NaN ₃ . | 2.5ml |
| Calibrator high: bovine serum, 0.2%NaN ₃ . | 2.5ml |
| FITC Label: anti-AFP monoclonal antibody labeled FITC, contains BSA, 0.2%NaN ₃ . | 7.5ml |
| ABEI Label: anti-AFP monoclonal antibody labeled ABEI, contains BSA, 0.2%NaN ₃ . | 7.5ml |
| All reagents are provided ready-to-use. | |

| Reagent Vials in kit box | |
|---|-------|
| Internal Quality Control: containing BSA, 0.2%NaN ₃ . (target value refer to Quality Control Information date sheet). | 2.0ml |

Internal quality control is only applicable with MAGLUMI system. Instructions for use and target value refer to Quality Control Information date sheet. User needs to judge results with their own standards and knowledge.

Accessories Required But Not Provided

| | |
|-------------------------------------|-----------------|
| MAGLUMI Reaction Module | REF: 630003 |
| MAGLUMI Prenatal Screening Software | REF:1301221 |
| MAGLUMI Starter 1+2 | REF: 130299004M |
| MAGLUMI Wash Concentrate | REF: 130299005M |
| MAGLUMI Light Check | REF: 130299006M |

Please order accessories from SNIBE or our representative.



Preparation of the Reagent Integral

Before the sealing is removed, gentle and careful horizontal shaking of the Reagent Integral is essential (avoid foam formation!) Remove the sealing and turn the small wheel of the magnetic microbeads compartment to and fro, until the colour of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic microbeads are automatically agitated and completely resuspended.

Do not interchange integral component from different reagents or lots!

Storage and Stability

- Sealed: Stored at 2-8°C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it's not going to be used on board during the next 12 hours.

- Keep upright for storage.

- Keep away from sunlight.

CALIBRATION AND TRACEABILITY

1) Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against the W.H.O.1st International Standard AFP.

2) 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

3) Frequency of Recalibration

- After each exchange of lot (Reagent Integral or Starter Reagents).
- Every 2 weeks and/or each time a new Integral is used (recommendation).
- After each servicing of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI..
- If controls are beyond the expected range.
- The room temperature has changed more than 5 °C (recommendation).

SPECIMEN COLLECTION AND PREPARATION

Sample material: serum

Collect 5.0ml venous blood into Blood Collection Tube. Standing at room temperature, centrifuging, separating serum part.

The serum sample is stable for up to 12 hours at 2-8°C. More than 12 hours, please packed, -20 °C can be stored for 30 days.

Avoid repeated freezing and thawing, the serum sample can be 018130729-V2.3-EN

only frozen and thawed two times. Stored samples should be thoroughly mixed prior to use (Vortex mixer).

Please ask local representative of SNIBE for more details if you have any doubt.

Vacuum Tubes

- Blank tubes are recommended type for collecting samples.
- Please ask SNIBE for advice if special additive must be used in sample collecting.

Specimen Conditions

- Do not use specimens with the following conditions:
 - heat-inactivated specimens;
 - Cadaver specimens or body fluids other than human serum;
 - Obvious microbial contamination.
- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for each sample to prevent cross contamination.
- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

Preparation for Analysis

- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed **thoroughly** after thawing by **low** speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.


Storage

- If testing will be delayed for more than 8 hours, remove serum from the serum separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 12 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

Shipping

Before shipping specimens, it is recommended that specimens be removed from the serum separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this section of the package insert.

WARNING AND PRECAUTIONS FOR USERS



- For use in *IN-VITRO* diagnostic procedures only.
- Package insert instructions must be carefully followed.

Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Safety Precautions

CAUTION: This product requires the handling of human specimens.

- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other infectious agents are absent; these reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially able to transmit infectious agents. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be autoclaved using an overkill approach. A minimum of one hour at 121°C is usually considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.
- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Bloodborne Pathogens¹³. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.
- For microbeads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface, please pay attention the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

TEST PROCEDURE

To ensure proper test performance, strictly adhere to the operating instructions of the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

| | |
|--------|--------------------------|
| 50µl | Sample, calibrator |
| +50µl | FITC Label |
| +50µl | ABEI Label |
| +20µl | Nano magnetic microbeads |
| 15 min | Incubation |
| 400µl | Cycle washing |
| 3s | Measurement |

DILUTION

Samples with concentrations above the measuring range can be diluted. After manual dilution, multiply the result by the dilution factor. After dilution by the analyzers, the analyzer software 018130729-V2.3-EN

automatically takes the dilution into account when calculating the sample concentration.

Availability of sample dilution by analyzer please refers to the MAGLUMI analyzer user software program. Dilution settings please follow MALGUMI analyzer operating instructions.

QUALITY CONTROL

Observe quality control guidelines for medical laboratories.

Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.

LIMITATIONS OF THE PROCEDURE

1) Limitations

Patients with malignancies may exhibit AFP values within the normal range. AFP concentrations may be elevated in case of liver cirrhosis, hepatitis or tyrosinaemia. Thus, AFP determination is more suitable for therapeutic monitoring and follow-up as well as for a comparison with histological results. AFP serum levels may only be interpreted in context with the clinical picture and other diagnostic procedures. The AFP assay should not be used as the only criterion for cancer screening.

2) Interfering Substances

No interference with test results is seen by concentrations of bilirubin<20mg/dl, haemoglobin<500mg/dl or triglycerides<1000mg/dl.

3) HAMA

Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

4) High-Dose Hook

No high-dose hook effect was seen for c-AFP concentrations up to 9000 IU/ml.

RESULTS

1) Calculation of Results

The analyzer automatically calculates the AFP concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in IU/ml. For further information please refer to the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI Operating Instructions.

Conversion factor: 1 ng/ml = 0.83 IU/ml

2) Interpretation of Results

- The result of AFP (Prenatal Screening) assay is calculated using the specific MAGLUMI Prenatal Screening software (REF: 1301221). Please check the software for reference result.
- Results may differ between laboratories due to variations in population and test method. If necessary, each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

1) Precision

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

| Intra-assay precision | | | |
|-----------------------|---------|---------|-----|
| Control | Control | Control | CV% |
| | | | |

| | | | |
|---------|---------|---------|------|
| Level 1 | Level 1 | Level 1 | 5.94 |
| Level 2 | Level 2 | Level 2 | 5.72 |
| Level 3 | Level 3 | Level 3 | 5.34 |

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

| Inter-assay precision | | | |
|-----------------------|-------------|-----------|------|
| Control | Mean(IU/ml) | SD(IU/ml) | CV% |
| Level 1 | 8.45 | 0.82 | 9.75 |
| Level 2 | 62.49 | 5.88 | 9.41 |
| Level 3 | 176.64 | 16.18 | 9.16 |

2) Analytical Sensitivity

The sensitivity is defined as the concentration of AFP equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 1.13IU/ml.

3) Specificity

The specificity of the AFP assay system was assessed by measuring the apparent response of the assay to various potentially cross reactive analytes.

| Compound | Concentration | Cross reactivity |
|----------|---------------|------------------|
| CEA | 200 ng/ml | 0.75% |
| CA125 | 200 IU/ml | 0.75% |
| CA15-3 | 200 IU/ml | 0.75% |

4) Recovery

Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratio with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

| Expected | Mean Measuring | Recovery |
|-------------|----------------|----------|
| 229.93IU/ml | 221.51IU/ml | 96% |

5) Linearity

Use AFP calibrator to prepare the six point standard curve, measuring all points' RLU except point A, and then do four parameter linear fitting in double logarithm coordinate, the absolute linear correlation coefficient(r) should be bigger than 0.9800.

| Calibrator Point | Concentration IU/ml | Absolute linear correlation coefficient (r) |
|------------------|---------------------|---|
| A | 0 | |
| B | 4.5 | r=0.9930 |
| C | 18 | |
| D | 45 | |
| E | 180 | |
| F | 450 | |

6) Method comparison

A comparison of MAGLUMI AFP (y) with a commercially available AFP test (x) using clinical samples gave the following correlations (IU/ml):

Linear regression

$$y = 1.12x - 12.6$$

$$r = 0.973$$

Number of samples measured: 178

The sample concentrations were between 4.5 and 405 IU/ml

REFERENCES

1. Aoyagi Y. Carbohydrate-based measurements of alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. *Glycoconjugate Journal* 1995; 12: 194-199
2. Bock JL. Current Issues in Maternal Serum: Alpha-

Fetoprotein Screening (Review Article). *Am J Clin Pathol* 1992; 97: 541-554

3. Brewer JA, Tank ES. Yolk sac tumors and alpha-fetoprotein in first year of life. *Urology* 1993; 42 (1): 79-80
4. Brizot ML et al. First trimester maternal serum alpha-fetoprotein in fetal trisomies. *Br J Obstet Gynaec* 1995; 102: 31-34
5. Burditt LJ et al. Detection of Hepatocellular Carcinoma-Specific Alpha-Fetoprotein by Isoelectric Focusing. *Cancer* 1994; 74 (1): 25-29
6. Johnson PJ et al. Germ Cell Tumors Express a Specific Alpha-Fetoprotein Variant Detectable by Isoelectric Focusing. *Cancer* 1995; 75(7): 1663-1668
7. Mora J et al. alpha-fetoprotein-Concanavalin A Binding as a Marker to Discriminate Between Germ Cell Tumours and Liver Diseases. *Eur J Cancer* 1995; 31A(13/14): 2239-2242